Eribulin

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1141 publications

Trastuzumab deruxtecan plus pertuzumab as a substantial advancement in previously untreated patients with HER2-positive metastatic breast cancer.

Trastuzumab deruxtecan plus pertuzumab as a substantial advancement in previously untreated patients with HER2-positive metastatic breast cancer.

Journal: European review for medical and pharmacological sciences

Published: September 01, 2026

Concurrent preoperative eribulin and radiation for resectable retroperitoneal liposarcoma: a phase 1B study.

Concurrent preoperative eribulin and radiation for resectable retroperitoneal liposarcoma: a phase 1B study.

Journal: Cancer treatment and research communications

Published: June 04, 2026

Artificial intelligence for anticancer drug discovery from natural products of macroalgae and sponges: A systematic review.

Artificial intelligence for anticancer drug discovery from natural products of macroalgae and sponges: A systematic review.

Journal: Computational biology and chemistry

Published: June 04, 2026

Predictors of Discontinuation of Eribulin Therapy for Metastatic Breast Cancer: A Retrospective Cohort Study.

Predictors of Discontinuation of Eribulin Therapy for Metastatic Breast Cancer: A Retrospective Cohort Study.

Journal: Anticancer research

Published: May 21, 2026

A case of recurrent breast cancer with severe hepatic dysfunction: Integrating narrative-based medicine and clinical decision-making.

A case of recurrent breast cancer with severe hepatic dysfunction: Integrating narrative-based medicine and clinical decision-making.

Journal: Palliative & supportive care

Published: May 14, 2026

The Evolving Landscape of Systemic Therapy for Liposarcoma.

The Evolving Landscape of Systemic Therapy for Liposarcoma.

Journal: Cancers

Published: April 21, 2026

Inavolisib and lenvatinib for PIK3CA-mutated refractory splenic angiosarcoma: a case report.

Inavolisib and lenvatinib for PIK3CA-mutated refractory splenic angiosarcoma: a case report.

Journal: Anti-cancer drugs

Published: April 15, 2026

Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer.

Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer.

Journal: Breast cancer (Tokyo, Japan)

Published: March 30, 2026

Eribulin for patients with metastatic breast cancer in England 2012-2021: Survival outcomes and 30-day mortality.

Eribulin for patients with metastatic breast cancer in England 2012-2021: Survival outcomes and 30-day mortality.

Journal: Breast (Edinburgh, Scotland)

Published: March 03, 2026

Minimal important differences of EORTC QLQ-C30 and QLQ-BR23 for metastatic breast cancer patients in a Japanese population: results from the RESQ trial.

Minimal important differences of EORTC QLQ-C30 and QLQ-BR23 for metastatic breast cancer patients in a Japanese population: results from the RESQ trial.

Journal: Breast cancer (Tokyo, Japan)

Published: February 12, 2026

Across Borders and Histologies: Rethinking Endpoints for Vascular Sarcoma Trials.

Across Borders and Histologies: Rethinking Endpoints for Vascular Sarcoma Trials.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 25, 2026

Efficacy and safety of eribulin therapy for breast cancer with liver metastasis: a retrospective real-world study.

Efficacy and safety of eribulin therapy for breast cancer with liver metastasis: a retrospective real-world study.

Journal: Frontiers in oncology

Published: January 25, 2026

Showing 1-12 of 1,141

Last Updated: 09/26/2026